Safety and effectiveness of adalimumab in a clinical setting that reflects Canadian standard of care for the treatment of rheumatoid arthritis (RA): Results from the CanACT study

BMC Musculoskeletal Disorders

Volumn 12, Issue , 2011, Pages

  Haraoui, Boulos ^a   Cividino, Alfred ^b   Stewart, Jacqueline ^c   Guérette, Benot ^d   Keystone, Edward C ^e  

^a NOTRE DAME HOSPITAL   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c Penticton Regional Hospital   (Canada)

^d Abbott   (France)

^e MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; PREDNISONE; SALAZOSULFAPYRIDINE; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ADVERSE DRUG REACTION; AGED; ARTICLE; BACTERIAL ARTHRITIS; BREAST CYST; CANADA; CELLULITIS; CONGESTIVE HEART FAILURE; DEATH; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EOSINOPHIL COUNT; FATIGUE; FEMALE; FOOT DISEASE; GASTROESOPHAGEAL REFLUX; HEADACHE; HEART INFARCTION; HUMAN; INJECTION SITE BURNING; INJECTION SITE CONTUSION; INJECTION SITE DERMATITIS; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE INFLAMMATION; INJECTION SITE IRRITATION; INJECTION SITE MASS; INJECTION SITE PRURITUS; INJECTION SITE RASH; INJECTION SITE STINGING; INJECTION SITE SWELLING; INJECTION SITE WARMTH; LEUKOCYTE COUNT; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REGURGITATION; MULTICENTER STUDY; NAUSEA; NEUTROPHIL COUNT; OPEN STUDY; OUTCOME ASSESSMENT; PANCREATITIS; PNEUMONIA; POSTOPERATIVE INFECTION; PROSPECTIVE STUDY; PRURITUS; PYELONEPHRITIS; RASH; REMISSION; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SEPTICEMIA; SIDE EFFECT; STANDARD; STAPHYLOCOCCUS INFECTION; THROMBOCYTE COUNT; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; WOUND INFECTION; CLINICAL TRIAL; COHORT ANALYSIS; HEALTH CARE POLICY; HEALTH CARE QUALITY; MIDDLE AGED; PATHOLOGY; RADIOGRAPHY; TIME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CANADA; COHORT STUDIES; FEMALE; HEALTH POLICY; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF HEALTH CARE; TIME FACTORS; TREATMENT OUTCOME;

EID: 81155138345     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-12-261     Document Type: Article

References (26)

1. Arthritis in Canada: an ongoing challenge. 2003
2. Long-term outcome of treating rheumatoid arthritis: results after 20 years. Scott DL, Symmons DP, Coulton BL, Popert AJ, Lancet 1987 1 1108 1111 2883443
3. Taking mortality in rheumatoid arthritis seriously - predictive markers, socioeconomic status and comorbidity. Pincus T, Callahan LF, J Rheumatol 1986 13 841 845 3820193 (Pubitemid 17203909)
4. Cytokine pathways and joint inflammation in rheumatoid arthritis. Choy EH, Panayi GS, N Engl J Med 2001 344 907 916 10.1056/NEJM200103223441207 11259725 (Pubitemid 32224400)
5. Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. Saxne T, Palladino MA, Heinegard D, Talal N, Wollheim FA, Arthritis Rheum 1988 31 1041 1045 10.1002/art.1780310816 3136775
6. Tumour necrosis factor in synovial exudates. Di Giovine FS, Nuki G, Duff GW, Ann Rheum Dis 1988 47 768 772 10.1136/ard.47.9.768 3263088
7. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. Firestein GS, Alvaro-Gracia JM, Maki R, J Immunol 1990 144 3347 3353 2109776 (Pubitemid 20146364)
8. Generation of fully human anti-TNF antibody D2E7. Salfeld J, Kaymakcalan Z, Tracey D, Roberts A, Kamen R, ARTHRITIS RHEUM 1998 41 57 Abstract Number: 147
9. Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis. Barrera P, Joosten LA, den Broeder AA, van de Putte LB, van Riel PL, van den Berg WB, Ann Rheum Dis 2001 60 660 669 10.1136/ard.60.7.660 11406520 (Pubitemid 32588369)
10. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, Fischkoff SA, Chartash EK, J Rheumatol 2003 30 2563 2571 14719195 (Pubitemid 37549331)
11. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK, Arthritis Rheum 2003 48 35 45 10.1002/art.10697 12528101 (Pubitemid 36091645)
12. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, Fischkoff SA, Chartash EK, Arthritis Rheum 2004 50 1400 1411 10.1002/art.20217 15146409 (Pubitemid 38608061)
13. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. van de Putte LB, Atkins C, Malaise M, Sany J, Russell AS, van Riel PL, Settas L, Bijlsma JW, Todesco S, Dougados M, et al. Ann Rheum Dis 2004 63 508 516 10.1136/ard.2003.013052 15082480 (Pubitemid 38530193)
14. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, Sharp J, Perez JL, Spencer-Green GT, Arthritis Rheum 2006 54 26 37 10.1002/art.21519 16385520 (Pubitemid 43122183)
15. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Weinblatt ME, Keystone EC, Furst DE, Kavanaugh AF, Chartash EK, Segurado OG, Ann Rheum Dis 2006 65 753 759 10.1136/ard.2005.044404 16308341 (Pubitemid 43799174)
16. Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIER. van der Heijde D, Breedveld FC, Kavanaugh A, Keystone EC, Landewe R, Patra K, Pangan AL, J Rheumatol 2010 37 2237 2246 10.3899/jrheum.100208 20889601
17. Clinical Consequences of Delayed Addition of Adalimumab to Methotrexate Therapy Over 5 Years in Patients with Rheumatoid Arthritis. Keystone EC, Kavanaugh A, Weinblatt ME, Patra K, Pangan AL, J Rheumatol 2011
18. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al. Arthritis Rheum 1988 31 315 324 10.1002/art.1780310302 3358796 (Pubitemid 18091653)
19. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL, Arthritis Rheum 1995 38 44 48 10.1002/art.1780380107 7818570
20. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. Fries JF, Spitz PW, Young DY, J Rheumatol 1982 9 789 793 7175852
21. The Disease Activity Score and the EULAR response criteria. Fransen J, van Riel PL, Clin Exp Rheumatol 2005 23 93 99 16273792
22. Why we need observational studies to evaluate the effectiveness of health care. Black N, Bmj 1996 312 1215 1218 10.1136/bmj.312.7040.1215 8634569 (Pubitemid 26136714)
23. A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. Curtis JR, Jain A, Askling J, Bridges SL, Carmona L, Dixon W, Finckh A, Hyrich K, Greenberg JD, Kremer J, et al. Semin Arthritis Rheum 2010 40 2 14 e11 10.1016/j.semarthrit.2010.03.003 20674669
24. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Bombardieri S, Ruiz AA, Fardellone P, Geusens P, McKenna F, Unnebrink K, Oezer U, Kary S, Kupper H, Burmester GR, Rheumatology (Oxford) 2007 46 1191 1199 10.1093/rheumatology/ kem091 (Pubitemid 47053782)
25. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Burmester GR, Mease P, Dijkmans BA, Gordon K, Lovell D, Panaccione R, Perez J, Pangan AL, Ann Rheum Dis 2009 68 1863 1869 10.1136/ard.2008.102103 19147611
26. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Schiff MH, Burmester GR, Kent JD, Pangan AL, Kupper H, Fitzpatrick SB, Donovan C, Ann Rheum Dis 2006 65 889 894 16439435